Who
GILEAD SCIENCES, INC.
10% owner
Company insider
Files Form 4 as: 10% owner, Assembly Biosciences; 10% owner, Xilio Therapeutics; 10% owner, Arcus Biosciences; 10% owner, Kyverna Therapeutics; 10% owner, Kalaris Therapeutics; 10% owner, Achillion Pharmaceuticals.
In numbers
- Trades disclosed
- 32
- Buys
- 11
- Sells
- 0
- Bought
- $628.1M
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 31 Oct 2006
- Last trade
- 26 May 2026
- Last filed
- 27 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 May 2026filed 27 May 2026 | ASMB Assembly BiosciencesBiotechnology | SEC FORM 4 Code A | $12.5M471,698 at $26.50 | filing |
| 26 May 2026filed 27 May 2026 | ASMB Assembly BiosciencesBiotechnology | SEC FORM 4 Code A | $12.5M471,698 at $26.50 | filing |
| 13 Feb 2026filed 17 Feb 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $2.0M3,739,000 at $0.5349 | filing |
| 13 Feb 2026filed 17 Feb 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $2.0M3,739,000 at $0.53 | filing |
| 26 Nov 2025filed 1 Dec 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code X | $10.0M13,335,000 at $0.75 | filing |
| 26 Nov 2025filed 1 Dec 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code X | —13,335,000 at $0.00 | filing |
| 8 Aug 2025filed 3 Oct 2025 | ASMB Assembly Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | —1,147,960 | filing |
| 8 Aug 2025filed 3 Oct 2025 | ASMB Assembly Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | —1,147,960 | filing |
| 8 Aug 2025filed 3 Oct 2025 | ASMB Assembly BiosciencesBiotechnology | SEC FORM 4 Bought | —2,295,920 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —13,335,000 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —13,335,000 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —13,335,000 | filing |
| 5 Jun 2025filed 6 Jun 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —13,335,000 | filing |
| 18 Feb 2025filed 20 Feb 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Bought | $15.0M1,363,636 at $11.00 | filing |
| 19 Dec 2024filed 23 Dec 2024 | ASMB Assembly BiosciencesBiotechnology | SEC FORM 4 Bought | $20.1M940,499 at $21.37 | filing |
| 18 Dec 2024filed 19 Dec 2024 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $6.3M6,092,816 at $1.04 | filing |
| 18 Dec 2024filed 19 Dec 2024 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.8M1,759,978 at $1.04 | filing |
| 17 Jun 2024filed 20 Jun 2024 | ASMB Assembly Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | —179,500 | filing |
| 17 Jun 2024filed 20 Jun 2024 | ASMB Assembly BiosciencesBiotechnology | SEC FORM 4 Bought | —179,500 | filing |
| 2 Apr 2024filed 3 Apr 2024 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $3.0M3,882,450 at $0.76 | filing |
News
Gilead Sciences, Inc. $GILD Stock Acquired by First Citizens Bank & Trust Co.dailypolitical.com · 14 Oct 2026Saudi Central Bank Grows Stock Position in Gilead Sciences, Inc. $GILDdailypolitical.com · 6 Sep 2026Arcus Biosciences Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer DataRCUS · investors.com · 20 Oct 2026Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical ContrastRCUS · themarketsdaily.com · 19 Oct 2026Valion Bio, Inc. Common Stock (NASDAQ:VBIO) vs. Arcus Biosciences (NYSE:RCUS) Head-To-Head ComparisonRCUS · themarketsdaily.com · 18 Oct 2026Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Rated "Moderate Buy" by Wall Street AnalystsKYTX · dailypolitical.com · 10 Oct 2026Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026KYTX · manilatimes.net · 7 Oct 2026
2 headlines in the last 90 days name GILEAD SCIENCES, INC.; 5 articles from the last 14 days about the 5 companies they traded most, at most three about any one of them.